{"id":1002238,"date":"2026-09-09T23:33:42","date_gmt":"2026-09-10T03:33:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\/"},"modified":"2026-09-09T23:33:42","modified_gmt":"2026-09-10T03:33:42","slug":"kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\/","title":{"rendered":"Kaplan Fox & Kilsheimer LLP Alerts Beta Bionics, Inc. (NASDAQ: BBNX) Investors to a Securities Class Action Deadline on November 3, 2026"},"content":{"rendered":"
\n

NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) — Kaplan Fox & Kilsheimer LLP<\/u><\/a> announces that a class action lawsuit has been filed against Beta Bionics, Inc. (\u201cBeta Bionics\u201d or the \u201cCompany\u201d) (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the \u201cClass Period\u201d).<\/p>\n

\n
\n CLICK HERE TO JOIN THE CASE<\/u>
\n <\/a>\n <\/p>\n

\n If you are an investor in Beta Bionics and have suffered losses, you may <\/strong>
\n
\n
\n CLICK HERE<\/u>
\n <\/strong>
\n <\/a>
\n to contact us. You may also contact Kaplan Fox by emailing <\/strong>
\n
\n
\n pmayer@kaplanfox.com<\/u>
\n <\/strong>
\n <\/a>
\n or by calling (646) 315-9003.<\/strong>\n <\/p>\n

\n DEADLINE REMINDER<\/strong>: If you are a member of the proposed Class, you may move the court no later than November 3, 2026 <\/u><\/strong>to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.<\/p>\n

Beta Bionics is a commercial-stage medical device company, serving patients with diabetes through the iLet Bionic Pancreas insulin pump (\u201ciLet\u201d), an automated insulin delivery system. The complaint alleges that throughout the Class Period, Beta Bionics received thousands of complaints from iLet customers, including numerous reports of serious, life-threatening hypoglycemia caused by device malfunctions that required hospitalization to treat. The root cause of these malfunctions was allegedly iLet\u2019s extremely aggressive dosing algorithm.<\/p>\n

The truth was allegedly revealed through a series of disclosures starting on January 8, 2026 when Beta Bionics surprised investors with a miss on the key metric of new iLet patient starts, which was followed by a 37% one-day stock price decline. Finally, on February 24, 2026, the full truth was allegedly revealed when the U.S. Food and Drug Administration (the \u201cFDA\u201d) publicly released its warning letter detailing a litany of violations and Defendants\u2019 failure to correct them, and contradicting months of Defendants\u2019 public statements that all back-filed complaints were for entirely benign issues. According to the complaint, the warning letter made clear that Defendants\u2019 prior interpretation of FDA reporting requirements had not been reasonable, and had excluded numerous serious patient incidents that clearly should have been reported.<\/p>\n

\n WHY CONTACT KAPLAN FOX?<\/strong>\n <\/p>\n

Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.<\/p>\n

Kaplan Fox is widely regarded as one of the nation’s premier plaintiffs’ securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America<\/em>\u2014the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act\u2014$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors<\/em>, and a $475 million settlement in In re Merrill Lynch<\/em>.<\/p>\n

For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.<\/p>\n

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.<\/p>\n

If you have any questions about this Notice, your rights, or your interests, please contact:<\/p>\n

\n CONTACT:<\/strong>\n <\/p>\n

Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
pmayer@kaplanfox.com<\/u><\/a><\/p>\n

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1501
Oakland, California 94612
(415) 772-4704
lking@kaplanfox.com<\/u><\/a><\/p>\n

Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.<\/p>\n

\n
\n https:\/\/www.kaplanfox.com\/case\/beta-bionics-nasdaq-bbnx-class-action-lawsuit-learn-more-now\/<\/u>
\n <\/a>\n <\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) — Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (\u201cBeta Bionics\u201d or the \u201cCompany\u201d) (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the \u201cClass Period\u201d). CLICK HERE TO JOIN THE CASE If you are an investor in Beta Bionics and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than November 3, 2026 to serve … <\/p>\n

Continue reading “Kaplan Fox & Kilsheimer LLP Alerts Beta Bionics, Inc. (NASDAQ: BBNX) Investors to a Securities Class Action Deadline on November 3, 2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1002238","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nKaplan Fox & Kilsheimer LLP Alerts Beta Bionics, Inc. (NASDAQ: BBNX) Investors to a Securities Class Action Deadline on November 3, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kaplan Fox & Kilsheimer LLP Alerts Beta Bionics, Inc. (NASDAQ: BBNX) Investors to a Securities Class Action Deadline on November 3, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) — Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (\u201cBeta Bionics\u201d or the \u201cCompany\u201d) (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the \u201cClass Period\u201d). CLICK HERE TO JOIN THE CASE If you are an investor in Beta Bionics and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than November 3, 2026 to serve … Continue reading "Kaplan Fox & Kilsheimer LLP Alerts Beta Bionics, Inc. (NASDAQ: BBNX) Investors to a Securities Class Action Deadline on November 3, 2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-10T03:33:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNDM1MSM3ODI2NTg3IzIwMjA4OTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kaplan Fox & Kilsheimer LLP Alerts Beta Bionics, Inc. (NASDAQ: BBNX) Investors to a Securities Class Action Deadline on November 3, 2026\",\"datePublished\":\"2026-09-10T03:33:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\\\/\"},\"wordCount\":706,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyNDM1MSM3ODI2NTg3IzIwMjA4OTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\\\/\",\"name\":\"Kaplan Fox & Kilsheimer LLP Alerts Beta Bionics, Inc. (NASDAQ: BBNX) Investors to a Securities Class Action Deadline on November 3, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyNDM1MSM3ODI2NTg3IzIwMjA4OTE=\",\"datePublished\":\"2026-09-10T03:33:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyNDM1MSM3ODI2NTg3IzIwMjA4OTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyNDM1MSM3ODI2NTg3IzIwMjA4OTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kaplan Fox & Kilsheimer LLP Alerts Beta Bionics, Inc. (NASDAQ: BBNX) Investors to a Securities Class Action Deadline on November 3, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kaplan Fox & Kilsheimer LLP Alerts Beta Bionics, Inc. (NASDAQ: BBNX) Investors to a Securities Class Action Deadline on November 3, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\/","og_locale":"en_US","og_type":"article","og_title":"Kaplan Fox & Kilsheimer LLP Alerts Beta Bionics, Inc. (NASDAQ: BBNX) Investors to a Securities Class Action Deadline on November 3, 2026 - Market Newsdesk","og_description":"NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) — Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (\u201cBeta Bionics\u201d or the \u201cCompany\u201d) (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the \u201cClass Period\u201d). CLICK HERE TO JOIN THE CASE If you are an investor in Beta Bionics and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than November 3, 2026 to serve … Continue reading \"Kaplan Fox & Kilsheimer LLP Alerts Beta Bionics, Inc. (NASDAQ: BBNX) Investors to a Securities Class Action Deadline on November 3, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-10T03:33:42+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNDM1MSM3ODI2NTg3IzIwMjA4OTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kaplan Fox & Kilsheimer LLP Alerts Beta Bionics, Inc. (NASDAQ: BBNX) Investors to a Securities Class Action Deadline on November 3, 2026","datePublished":"2026-09-10T03:33:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\/"},"wordCount":706,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNDM1MSM3ODI2NTg3IzIwMjA4OTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\/","name":"Kaplan Fox & Kilsheimer LLP Alerts Beta Bionics, Inc. (NASDAQ: BBNX) Investors to a Securities Class Action Deadline on November 3, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNDM1MSM3ODI2NTg3IzIwMjA4OTE=","datePublished":"2026-09-10T03:33:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNDM1MSM3ODI2NTg3IzIwMjA4OTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNDM1MSM3ODI2NTg3IzIwMjA4OTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaplan-fox-kilsheimer-llp-alerts-beta-bionics-inc-nasdaq-bbnx-investors-to-a-securities-class-action-deadline-on-november-3-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kaplan Fox & Kilsheimer LLP Alerts Beta Bionics, Inc. (NASDAQ: BBNX) Investors to a Securities Class Action Deadline on November 3, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1002238","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1002238"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1002238\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1002238"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1002238"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1002238"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}